Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
111.5 SEK | +6.70% | +8.78% | +41.86% |
May. 27 | Devyser Wins Tender for Thalassemia in Italy | CI |
May. 14 | Devyser Diagnostics AB Appoints Thomas Eklund as Member of the Board of Directors | CI |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 1,346 | 1,152 | 1,280 | 1,703 | - | - |
Enterprise Value (EV) 2 | 981 | 810.1 | 1,092 | 1,493 | 1,495 | 1,387 |
P/E ratio | -49.7 x | -24.7 x | -23.9 x | -59.3 x | 44.7 x | 21.3 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 14.4 x | 9.1 x | 7.56 x | 7.57 x | 4.97 x | 4.59 x |
EV / Revenue | 10.5 x | 6.4 x | 6.45 x | 6.64 x | 4.37 x | 3.74 x |
EV / EBITDA | -64.5 x | -18.7 x | -23.8 x | -136 x | 24.2 x | 14.2 x |
EV / FCF | -53 x | -12.6 x | -10.7 x | -29.3 x | 83.1 x | 15.8 x |
FCF Yield | -1.89% | -7.95% | -9.32% | -3.42% | 1.2% | 6.34% |
Price to Book | 3.37 x | 2.66 x | 3.35 x | 4.17 x | 3.6 x | - |
Nbr of stocks (in thousands) | 15,188 | 16,006 | 16,284 | 16,293 | - | - |
Reference price 3 | 64.41 | 48.08 | 52.71 | 68.22 | 68.22 | 68.22 |
Announcement Date | 2/24/22 | 2/21/23 | 2/20/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | 93.5 | 126.6 | 169.3 | 224.9 | 342.4 | 371.2 |
EBITDA 1 | - | -15.2 | -43.4 | -45.8 | -11 | 61.74 | 98 |
EBIT 1 | - | -21.2 | -52 | -58.9 | -26.2 | 45.69 | 76.2 |
Operating Margin | - | -22.67% | -41.07% | -34.79% | -11.65% | 13.35% | 20.53% |
Earnings before Tax (EBT) 1 | - | -21.9 | -52.7 | -54.4 | -27 | 46.14 | 71 |
Net income 1 | -10.91 | -20.7 | -46 | -53.6 | -29 | 38.08 | 86 |
Net margin | - | -22.14% | -36.33% | -31.66% | -12.89% | 11.12% | 23.17% |
EPS 2 | -0.000920 | -1.297 | -1.949 | -2.205 | -1.151 | 1.527 | 3.196 |
Free Cash Flow 1 | - | -18.5 | -64.4 | -101.7 | -51 | 18 | 88 |
FCF margin | - | -19.79% | -50.87% | -60.07% | -22.68% | 5.26% | 23.71% |
FCF Conversion (EBITDA) | - | - | - | - | - | 29.16% | 89.8% |
FCF Conversion (Net income) | - | - | - | - | - | 47.26% | 102.33% |
Dividend per Share 2 | - | - | - | - | - | - | - |
Announcement Date | 5/11/21 | 2/24/22 | 2/21/23 | 2/20/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 24.5 | 30.4 | 30.9 | 31.2 | 34.2 | 39.5 | 37.7 | 46.7 | 45.4 | 50.7 | 53.2 | 58.2 | 62.5 | 64.5 |
EBITDA | - | - | - | - | - | -16.3 | -11.1 | -4.1 | -14.2 | - | - | - | - | - |
EBIT 1 | -13.9 | -5.2 | -12.6 | -8.2 | -25.9 | -19.1 | -13.5 | -7.8 | -18.5 | -12.2 | -8 | -4 | -2.1 | -2 |
Operating Margin | -56.73% | -17.11% | -40.78% | -26.28% | -75.73% | -48.35% | -35.81% | -16.7% | -40.75% | -24.06% | -15.04% | -6.87% | -3.36% | -3.1% |
Earnings before Tax (EBT) | - | - | - | - | - | -19.3 | -13.8 | -5.2 | -16.2 | - | - | - | - | - |
Net income | - | - | - | - | - | -19.9 | -14.6 | -6 | -13.1 | - | - | - | - | - |
Net margin | - | - | - | - | - | -50.38% | -38.73% | -12.85% | -28.85% | - | - | - | - | - |
EPS | - | - | - | - | - | -0.8259 | -0.5650 | -0.2366 | -0.5328 | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 2/24/22 | 5/11/22 | 8/24/22 | 11/10/22 | 2/21/23 | 5/9/23 | 8/23/23 | 11/9/23 | 2/20/24 | 5/8/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - |
Net Cash position 1 | - | 365 | 342 | 188 | 210 | 207 | 316 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | -18.5 | -64.4 | -102 | -51 | 18 | 88 |
ROE (net income / shareholders' equity) | - | -7.79% | -10.8% | -13.1% | -8% | 8.89% | 21% |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share 2 | - | 19.10 | 18.10 | 15.80 | 16.40 | 19.00 | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | 2.2 | 7.9 | 11.5 | 24 | 8.76 | 13 |
Capex / Sales | - | 2.35% | 6.24% | 6.79% | 10.67% | 2.56% | 3.5% |
Announcement Date | 5/11/21 | 2/24/22 | 2/21/23 | 2/20/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.49% | 162M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- DVYSR Stock
- Financials Devyser Diagnostics AB